# Buying a Pharmacy

What independent pharmacies trade for, why the payer mix decides the margin before you do, and how script-file deals differ from whole-store ones.

Source: https://searchspheresource.com/guides/buying-a-pharmacy
Last checked: 2026-10-04

## Why Searchers Look at Pharmacies

Independent community pharmacy is a large, fragmented market under visible stress, which cuts both ways. NCPA's 2025 Digest counts 18,960 independent locations (about 36% of US retail pharmacies) doing a combined $103 billion, with the average store filling about 67,600 prescriptions a year on roughly $5.4 million of sales. Demand is chronic-medication demand: recurring, local, and referral-fed. Chain closures keep sending patients to independents, and many owners are pharmacists near retirement. The stress is real too: 2024 brought a ten-year low in gross profits, and the margin story below is the whole thesis. One more wall to know: North Dakota alone requires majority pharmacist ownership.

## What Pharmacies Trade For

The trade body's own deal calculator prices a [going concern](https://searchspheresource.com/glossary/going-concern) at an [EBITDA](https://searchspheresource.com/glossary/ebitda) multiplier of 3 to 3.5, applied to EBITDA plus half the owner's salary with inventory added on top; its worked example puts a $3.9M store with $270,000 of EBITDA at $1,268,000. The publisher's sold pharmacy listings run wider, half of transactions between 1.69x and 3.75x [SDE](https://searchspheresource.com/glossary/sde) across 2021 to 2025 on a 2.45x median, with a $325,000 median sale price. Two deal shapes exist: a whole-store purchase, and a script-file sale in which a buyer acquires the prescription files and inventory while the location closes. Inventory moves the total check either way.

## Reimbursement Decides the Margin

A pharmacy's [gross margin](https://searchspheresource.com/glossary/gross-margin) is set mostly by parties who never enter the store: pharmacy benefit managers and government programs. NCPA reports 52% of independent prescriptions ride Medicare Part D or Medicaid, and 2024 gross profits hit a ten-year low, with some scripts reimbursed below acquisition cost. Industry reporting credits the 2024 Medicare change with moving DIR adjustments to the point of sale, ending the [clawbacks](https://searchspheresource.com/glossary/clawback) taken after the fill, but the compression itself did not reverse. Diligence the margin per script by payer, not the blended number: a store can grow scripts and shrink profit at the same time.

## The Script File Is the Asset

What transfers in a pharmacy sale is a book of patients and their refills, and it moves on trust and continuity. Verify the file's trend (script counts, transfers in and out, refill persistence), because a declining file at a strong multiple is an overpriced deal wearing a good year. Continuity of the pharmacist-in-charge matters to both patients and the state board, and California and Florida both require one. The licensing sequence (a new state permit, [DEA registration](https://searchspheresource.com/glossary/dea-registration), NCPDP and NPI updates, payer contracting) has to be mapped before closing or the store cannot bill. The primary wholesaler agreement carries rebate tiers and purchase commitments worth reading line by line.

## What to Verify in Diligence

The record to assemble before the offer holds:

## Financeability Notes

Pharmacies finance under [SBA 7(a)](https://searchspheresource.com/glossary/sba-7a), and the $1.2M median acquisition loan in the FOIA data sits squarely in [searcher](https://searchspheresource.com/glossary/searcher) range, but lenders underwrite the reimbursement risk directly: expect questions on payer mix, per-script margin trend, and who the pharmacist-in-charge will be on day one. The seasoned [charge-off rate](https://searchspheresource.com/glossary/charge-off) for the industry runs below the pooled rate across every trade the site measures, which is the steady demand showing up in loan files even while margins compress. Inventory wants a [working-capital](https://searchspheresource.com/glossary/working-capital) line sized to real days on hand. In North Dakota, confirm the pharmacist-majority ownership structure before anything else is spent.

## Terms in This Industry

- **Front-end share**: Revenue from everything that is not a prescription, at a margin the prescriptions do not carry. Dispensing margins are set by contracts a small pharmacy does not negotiate, so the part of the business the owner actually controls is the front end and the clinical services beside it. Two pharmacies filling the same script count can therefore earn very differently. Split revenue and margin into dispensing, front end, and services for three years, because a shrinking front end under a flat script count is a business quietly becoming a contract.
- **DIR fees**: A benefit manager's price concession, clawed back after the fill until 2024 and now taken up front. Read the date before the number, because the mechanism moved. Until 2024 these were clawed back weeks after a fill, so a profitable prescription could become a loss and gross reimbursement was not a figure anybody could underwrite. From January 2024 the price concession has to show at the point of sale, which makes the remittance a figure you can underwrite and the trailing years incomparable. Normalize the seller's earnings across that line, and treat any three-year trend that ignores it as a chart of two different things.
- **PBM (pharmacy benefit manager)**: The middlemen who set what a pharmacy is paid for each prescription it fills. They hold the pricing power in this trade. Reimbursement terms, network access, and the fees above all flow from them, so the contracts and the mix decide whether the revenue is durable or merely current. Ask which plans drive the volume and what share of scripts each represents, because losing one network can take a fifth of the business overnight, and the decision will not be yours to appeal.
- **Generic dispensing rate**: The share of prescriptions filled with generics, where nearly all of the margin lives. Brand scripts move a great deal of revenue at almost no gross profit, so a pharmacy with high sales and a low generic rate is a large business and a small one at the same time. Ask for the rate by month with gross profit per script beside it, and ask what happens when a large brand goes generic, because that single event can change the shape of a year in either direction.
- **Closed-door pharmacy**: A pharmacy dispensing only to a defined population, such as a facility's residents, never walk-ins. Revenue concentrates in a handful of facility contracts and not across a neighborhood, so the diligence question is contract term and assignability, not script count and foot traffic. A book resting on one contract that expires inside a year is a different asset from a retail store at the same revenue, and it prices differently. Confirm the state licenses this class separately, because a retail permit does not always carry across.
- **Transfer-day inventory**: The count of controlled stock taken on the day of closing, closing one book and opening another. It is the mechanic that makes a pharmacy sale legal, and it is a single event with two owners. On the date of transfer a complete inventory of every controlled substance moving across is taken, and that one count serves as the seller's final inventory and the buyer's initial inventory, with a copy in each party's records. Schedule I and II substances additionally require the federal order form. The seller notifies the agency at least fourteen days ahead and stays responsible for the accuracy of records before the transfer date, while custody and maintenance pass to the buyer. The state license never travels: California and Florida both say in as many words that a pharmacy license or permit is not transferable.
- **Pseudoephedrine logbook**: The federal record and daily limit a pharmacy keeps on cold medicine sold from behind the counter. This is the front end's one closing-day item and it is easy to miss, because the guide's controlled-substance term sends everybody to look at the prescription side. The seller's self-certification is tied to a place of business and is not inherited with the keys, so a store that changes entity without filing holds a category it cannot legally sell from the first morning. Behind that sit two years of retained records the buyer takes over and can be asked to produce, plus the 3.6-gram daily cap per purchaser, which an undertrained counter breaks at volume. Read the last two years of logbook practice as a proxy for how the front end is actually run.
- **Pharmacist-in-charge (PIC)**: The licensed pharmacist responsible for a store's compliance, a role California and Florida both require. California's board must approve each proposed pharmacist-in-charge and issues no license without one, and Florida's investigates the one designated on the application, so who holds the role on day one is a licensing question before it is a staffing one. If the seller is the PIC, their departure has to be sequenced with the new permit, the DEA registration and the payer contracting, or the store cannot bill. If an employed pharmacist holds it, their retention is the deal inside the deal. Lenders ask the question directly, and a buyer who is not a pharmacist answers it with a signed employment agreement, not a plan.
- **Script-file sale**: The deal shape in which the buyer takes the prescription files and inventory and the seller's location closes. A whole-store purchase buys the location, the staff, the front end and the lease; a script-file sale buys the patients and their refills and moves them to the buyer's own counter, which is how a chain closure and an independent's growth meet. Price it on the file's trend, script counts, transfers in and out and refill persistence, and on how many patients actually follow, since a file moves on trust and the transfer notice is the moment they decide. Inventory is added at cost either way, and the controlled stock takes its own count on transfer day.

## What the Data Says

- Sold-pharmacy benchmarks on BizBuySell run a $325,000 median sale at 2.79x average earnings and 0.42x revenue. The wide gap between the $1.3M median revenue and the median sale is the script-margin problem priced in, and it is why the guide reads reimbursement before anything else. (BizBuySell, pharmacy valuation benchmarks (2021-2025 sold listings): https://www.bizbuysell.com/learning-center/valuation-benchmarks/pharmacy/)
- NCPA's 2025 Digest counts 18,960 independent pharmacy locations, about 36% of US retail pharmacies, in a $103 billion market, about $5.4 million a location. The average store filled 67,601 prescriptions in 2024, 52% of them under Medicare Part D or Medicaid, and 2024 gross profits sat at a ten-year low. (NCPA, 2025 Digest Report: https://ncpa.org/newsroom/news-releases/2025/10/19/ncpa-releases-2025-digest-report)
- North Dakota is the only state requiring pharmacies to be majority-owned by licensed pharmacists (a 1963 law voters kept in place by defeating 2014's Measure 7), so a non-pharmacist buyer needs a compliant structure or a different state. (Ballotpedia, North Dakota Measure 7 (2014): https://ballotpedia.org/North_Dakota_Pharmacy_Ownership_Initiative,_Measure_7_(2014))

Where they are, from Census County Business Patterns: California (3,295, https://searchspheresource.com/guides/states/california), New York (3,005, https://searchspheresource.com/guides/states/new-york) and Texas (2,400, https://searchspheresource.com/guides/states/texas) hold the most buyable ones.
Lender context, from the SBA loan-level file: Live Oak Banking Company (118), First Financial Bank (AR) (77), Byline Bank (27) wrote the most of this industry's 352 acquisition approvals (https://searchspheresource.com/data/acquisition-lending#by-industry).

## Who Else Is Buying in This Industry

- Guardian Pharmacy Services (Atlanta): Long-term care pharmacies serving assisted living, memory care, hospice, and behavioral health, acquired one and two at a time, the consolidator an LTC-focused pharmacy searcher meets first. Newest here: Wellness Concepts · 2026 · A Grottoes, Virginia long-term care pharmacy serving assisted-living, skilled-nursing, and behavioral-health communities. 7 more confirmed on its profile. (https://searchspheresource.com/buyers/guardian-pharmacy-services)
- Tarrytown Expocare Pharmacy (Austin, Texas): An Austin pharmacy built for group homes and behavioral health providers, buying closed-door long-term care pharmacies as it grows past thirty-five states by its own count. Newest here: Embrace Healthcare · 2026 · A closed-door long-term care pharmacy serving IDD providers in Ohio. 1 more confirmed on its profile. (https://searchspheresource.com/buyers/tarrytown-expocare)
- SIG Partners (Dallas, Texas, runs a searcher program): A family-owned Dallas holding company that counts thirty-eight businesses bought in five years and dates every close on its own portfolio page, buying to hold rather than to exit. Newest here: Gaddy Drug · 2025 · A Muskogee, Oklahoma pharmacy founded in 1949, running prescriptions, refills and deliveries for its own community. 1 more confirmed on its profile. (https://searchspheresource.com/buyers/sig-partners)

## How Big This Market Is

There are about 41,792 businesses in this industry. 34,046 of them (81%) have 5 to 99 employees: the band big enough to have something to sell, small enough to finance. Most of the rest are owner-operators with a job rather than a business to hand over. Census County Business Patterns (2023); how often they change hands is on https://searchspheresource.com/data/market-depth.

## Who the Law Lets Own This

North Dakota alone requires majority pharmacist ownership; California and Florida both require a licensed pharmacist in charge of each pharmacy.

How buyers structure around it: Non-pharmacist buyers keep a compliant pharmacist-in-charge and, in North Dakota, a pharmacist-majority structure or a different state.

Most of these rules are set state by state and change, so confirm the current one with the regulator that issues it and an attorney (https://searchspheresource.com/data/license-rules).

## What It Costs to Replace the Owner

The multiples are quoted on SDE, which adds the owner's pay back into earnings, so they hold only if you do the owner's job. For this trade the replacement is usually the pharmacist the license requires on site, paid a median of $140,910 a year nationally; at a 3x multiple that wage takes about $422,730 off what the business is worth to you. Pharmacists, BLS Occupational Employment and Wage Statistics (2025), national, all industries, before payroll taxes and benefits (https://searchspheresource.com/data/manager-wages).

## How Often These Loans Go Bad

Of the 136 SBA acquisition loans in this industry old enough for most failures to have shown up, 5 were charged off: a rate of 3.68%. Across every industry measured, the pooled rate is 4.20%, so this one runs cooler than the average acquisition. Computed from SBA loan-level data on a seasoned cohort; it counts loans already written off, so read it as a floor and as a ranking (https://searchspheresource.com/data/sba-default-rates).

## The Numbers That Run This Business

- Scripts filled per day, new versus refill
- Gross profit per script by payer
- Scripts reimbursed below acquisition cost
- Transfers in and out of the file
- Front-end and DME sales share
- Inventory days on hand at cost

Site index for machines: https://searchspheresource.com/llms.txt